Table 2 Multivariable-adjusted differences between placebo and paliperidone in the primary outcome (PSP) and mediators (WG, PANSS, and SAS score)

From: The role of PANSS symptoms and adverse events in explaining the effects of paliperidone on social functioning: a causal mediation analysis approach

 

PSP

PANSS

WG

SAS

Paliperidone 3 mg

8.42 (4.21, 12.64)

−3.47(−6.47, −0.47)

0.02 (0.01, 0.03)

0.14 (−0.19, 0.48)

Paliperidone 9 mg

9.74 (6.12, 13.35)

−3.91(−6.77, −1.06)

0.03 (0.02, 0.05)

0.71 (0.27, 1.16)

Paliperidone 15 mg

13.03 (9.21, 16.84)

−4.78(−7.86, −1.71)

0.04 (0.02, 0.05)

0.68 (0.24, 1.13)

Placebo

Ref

Ref

Ref

Ref

  1. All models adjusted for age, sex, race, country, relative day of disease onset, total PANSS score at baseline, PSP score at baseline, BARS score at baseline, SAS score at baseline, BMI at baseline. We report pooled estimates (pooled confidence intervals) from 50 multiple imputations
Back to article page